Biocon rises 5 per cent after launch of Ogivri in US market

PTI | Updated on December 03, 2019 Published on December 03, 2019

Shares of Biocon Ltd on Tuesday gained nearly 5 per cent in early trade after the company along with its partner Mylan announced the launch of biosimilar Ogivri in the US market.

The stock was trading 1.28 per cent up at Rs 289.60 on the BSE. During early market hours, the stock went up by 4.80 per cent to Rs 299.70.

On the NSE, the scrip was up by 1.56 per cent to Rs 290.25. It gained as much as 4.61 per cent to touch a high of Rs 299 in early trade.

Biotechnology major Biocon and drug firm Mylan NV on Monday announced the launch of biosimilar Ogivri, used for treatment of certain breast and gastric cancers, in the US market.

 “The US launch of Ogivri, the biosimilar trastuzumab co-developed by Biocon Biologics and Mylan, marks a significant milestone in our biosimilars journey,” Biocon Biologics CEO Christiane Hamacher, said.

Published on December 03, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.